• ORIGINAL RESEARCH • EVIDENCE BASED MEDICINE
• GENERAL PSYCHIATRY

Seroquel Once a Day: A Randomized, Double-Blind, Placebo-Controlled Study—
This 6-week, randomized, double-blind study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia resulting in the efficacy of quetiapine XR versus placebo in patients with schizophrenia was demonstrated for quetiapine XR 600 mg/day.
Jean-Pierre Lindenmayer, David Brown, Sherry Liu, Martin Brecher, and Didier Meulien, on behalf of the Study 41 investigators

New Patient-Rated Symptom Scale for GAD—
The majority of clinical outcome assessments developed for generalized anxiety disorder (GAD) may not efficiently and sensitively reflect heterogeneous symptom clusters from a patient perspective. The Patient-Rated Troubling Symptoms Scale for Anxiety (PaRTS-A) instrument was developed to provide an individualized assessment of patient relevant GAD symptoms.
Gahan J. Pandina, Dennis A. Revicki, Leah Kleinman, Ibrahim Turkoz, Jasmanda Wu, Ramy Mahmoud, Georges M. Gharabawi

Take Your Corners: Benzodiazepines vs. Newer Antidepressants in Anxiety Disorders —
The investigators performed a systematic review of controlled trials on anxiety disorders treatment (generalized anxiety disorder, panic disorder, social phobia and post traumatic stress disorder) published from 1980 to 2006, and identified trials comparing the efficacy of benzodiazepines with that of antidepressants.
Patricia Berney, Demian Halperin, Rodrigo Tango, Isabelle Daeniker-Dayer, Pierre Schulz

REVAMP: Augmenting Meds with Psychotherapy—Rationale & Design—
This report presents the rationale, design, and baseline sample characteristics for the REVAMP study. This project is a multisite clinical trial designed to evaluate the efficacy of augmenting state-of-the-art pharmacotherapy with psychotherapy in chronically depressed patients who fail to respond or respond incompletely to an initial trial of antidepressant medication.
Madhukar H. Trivedi, James H. Kocsis, Michael E. Thase, David W. Morris, Stephen R. Wisniewski, Andrew C. Leon, Alan J. Gelenberg, Daniel N. Klein, George Niederehe, Alan F. Schatzberg, Philip T. Ninan, Martin B. Keller

Bipolar REDUX: Stimulant-Associated Mania/Hypomania in Bipolar Patients—
Stimulants have been used to treat ADHD or augment bipolar depression treatment in patients with bipolar disorder. However, the effects of stimulant treatment in BD patients have been insufficiently studied. To date, this is the largest study on amphetamine/methylphenidate treatment and associated mania/hypomania in BD patients.
Aliza P. Wingo, S. Nassir Ghaemi

The 500—STEP-BD and the Correlates of Functioning—
The study included the first 500 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Its primary aim was to describe unique correlates of functioning in bipolar disorder.
Laszlo Gyulai, Mark S. Bauer, Lauren B. Marangell, Ellen B. Dennehy, Michael E. Thase, Michael W. Otto, Hongwei Zhang, Stephen R. Wisniewski, David J. Miklowitz, Mark H. Rapaport, Claudia F. Baldassano, and Gary S. Sachs, for the STEP-BD Investigators